Core Viewpoint - Kunming Pharmaceutical Group has been awarded the "Supply Chain Influence Award" for its outstanding practices in Environmental, Social, and Governance (ESG) areas, highlighting its commitment to integrating economic efficiency with social responsibility [1] Group 1: Environmental Practices - The company has established a systematic approach to environmental management, leveraging Yunnan's biodiversity with a GACP planting base covering 128,000 acres for traditional medicinal materials [4] - Kunming Pharmaceutical has implemented a heat recovery system at its manufacturing center, saving 3,200 tons of standard coal annually, and has reduced energy consumption per unit of output by 28.6% compared to 2020, with a wastewater reuse rate exceeding 65% [4] - The company collaborates with the Kunming Institute of Botany to cultivate endangered medicinal materials, maintaining a gene resource bank with over 1,200 species of medicinal plant seeds, ensuring sustainable resource utilization [4] Group 2: Supply Chain and Global Competitiveness - Kunming Pharmaceutical has developed a competitive international supply chain network, producing artemisinin and three derivatives, with three products included in the WHO's malaria treatment guidelines [4] - The company has built an SAP intelligent supply chain platform for visual management of procurement, production, and logistics, and established a blockchain-based traceability system for medicinal materials [5] Group 3: Social Responsibility - The company actively engages in various charitable activities, including disaster relief and educational support, contributing to social development and community building [5] - The "Sanqi Bank" model has increased the income of 246,000 farmers, with an average annual income increase of 12,000 yuan, positively impacting rural revitalization [5] - Employee welfare is prioritized, with an average training duration of 152 hours per R&D staff member in 2024 and a skill certification coverage rate of 98% for technical workers [5] Group 4: Future Outlook - Kunming Pharmaceutical aims to continue its commitment to sustainable development and optimize supply chain management to contribute to the high-quality development of the traditional Chinese medicine industry [6]